Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD168077 is a potent and selective small molecule agonist of the dopamine D4 receptor, with a Ki of 8.7 nM and >400-fold selectivity over D2 and >300-fold over D3 dopamine receptor subtypes[1][9][6]. It is used primarily as a research tool to investigate D4 receptor pharmacology and function, particularly in neurobiological and behavioral studies. PD168077 has been shown to induce penile erection in animal models by acting on D4 receptors in the paraventricular nucleus of the hypothalamus and increasing central oxytocinergic neurotransmission, with involvement of nitric oxide pathways[3][4][7]. It is centrally active in vivo and has also been used in studies related to synaptic effects in prefrontal cortical neurons.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PD168077.